对细胞毒性有效载荷应用中S-Trityl-l-Cysteine衍生物的基于药的结构优化
Taiki Ichida1,2, Naohisa Ogo1, Keisuke Murase1
1Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka 422-8526, Japan.
ACS medicinal chemistry letters
|October 15, 2025
概括
新的S-trityl-L-cysteine (STLC) 衍生物被开发为用于癌症治疗的强有力的激素螺旋蛋白 (KSP) 抑制剂. 这些STLC衍生物还显示出作为抗体-药物合物 (ADC) 的链接器有效载荷的前景.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 药物发现 药物发现 药物发现
背景情况:
- 素螺旋蛋白 (KSP) 是一个经过验证的癌症点,具有独特的作用机制.
- S-trityl-L-cysteine (STLC) 衍生物是已知的KSP抑制剂,但需要进一步优化.
- 抗体-药物联合体 (ADC) 提供向的癌症治疗,需要有效的链接器-有效载荷系统.
研究的目的:
- 设计和合成新的STLC衍生物,以改善KSP抑制的物理化学特性.
- 为了确定负责KSP抑制的最小药.
- 评估STLC衍生物作为ADC中的酶可分离的链接器有效载荷的潜力.
主要方法:
- 基于STLC衍生物的结构设计的分析.
- 新型STLC衍生物的化学合成,包括rac-1-C和2-C.
- 对KSP抑制活性 (GI50) 和结构-活性关系的评估.
- 合成和评估氨酸-氨酸-p-aminobenzyloxycarbonyl (VC) 链接器-STLC结合物用于甲素B介导释放.
主要成果:
- 合成了新型STLC衍生物,其中的2-C化合物表现出强大的KSP抑制 (GI50=1.2nM对HCT116).
- 化合物2-C被确定为KSP抑制的最小药.
- 可以通过酶切割的VC-linker-STLCs成功合成,证明了cathepsin B介导的有效载荷释放.
- 有效载荷结构影响了VC-linker-STLCs的裂变动力学.
结论:
- 优化的STLC衍生物代表了癌症治疗中可望的一类KSP抑制剂.
- 最少的药解剂2-C为进一步的药物开发提供了基础.
- 作为ADC的链接器有效载荷,VC-链接器-STLC是可行的,具有针对性药物输送的潜力.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K